- STOPAIN(R) to use Invisicare(R) to enhance its product line
LAS VEGAS, April 11 /CNW/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI)
(Website: www.skinvisible.com) is pleased to announce it has signed an
agreement to license a new topical analgesic formula with Invisicare(R), its
patented polymer delivery system, to DRJ Group Inc., makers of STOPAIN(R).
STOPAIN, a leading over-the-counter topical pain reliever in the $250
million topical analgesic market, will be extending its product line with a
new cream formulation which incorporates Invisicare as its delivery system.
The addition of Invisicare will keep this product on the skin for an extended
period of time, four hours or more, providing on-going relief to people
suffering from muscle stiffness, arthritis or muscle strains.
"We are very pleased with this partnership with Skinvisible as their
delivery system brings added value to our product and ultimately to our
customers that use STOPAIN," said Mr. Robert Miller, President and CEO of DRJ
Group Inc. "By including Invisicare, we are offering our customers a product
that is different from anything else currently on the market. We expect this
advantage to be well received by both the trade and the customer."
"This licensing agreement with DRJ Group is a notable step for
Skinvisible as our brand Invisicare will now have nation-wide exposure to
consumers in 25,000 pharmacies," said Mr. Terry Howlett, President and CEO of
Skinvisible. "We look forward to working closely with the STOPAIN group to
find more opportunities to incorporate our technology with their pain relief
Skinvisible's business model is focused on licensing its proprietary
formulations with Invisicare to pharmaceutical and cosmeceutical companies as
well as assisting companies in revitalizing or enhancing their existing skin
care products. In addition to the polymer revenue, Skinvisible receives a
combination of research and development fees, upfront license fees, and
ongoing royalties for the life of the patent.
Skinvisible has patented its technology and trademarked its polymer
delivery system, Invisicare. Invisicare is a combination of hydrophilic and
hydrophobic polymers that hold active ingredients on the skin for extended
periods of time. They are non-occlusive and allow normal skin respiration and
perspiration while moisturizing and protecting against exposure from a wide
variety of environmental irritants. See: www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Headquartered in Las Vegas, Nevada, Skinvisible Pharmaceuticals is a
research-and-development company whose primary business objective is to
license its technology and formulated products to manufacturers of Rx and OTC
skincare products. See www.skinvisible.com
About DRJ Group Inc.
DRJ, founded in 1991, markets its STOPAIN branded pain relievers in over
25,000 independent pharmacies and national chain drug stores including
Walgreens, CVS, RiteAid, Eckerds, Brooks and Longs Drug.
This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks and
uncertainties associated with an emerging company. Actual results could
differ materially from those projected in the forward looking statements as a
result of risk factors discussed in Skinvisible, Inc. reports on file with the
U.S. Securities and Exchange Commission (including, but not limited to, a
report on Form 10K for the year ending December 31, 2006.)
Terry Howlett, President/CEO
Skinvisible Pharmaceuticals, Inc
For further information:
For further information: Terry Howlett, President/CEO of Skinvisible
Pharmaceuticals, Inc, +1-702-433-7154, email@example.com Web Site: